Vis Cancer Med
Volume 3, 2022
|Number of page(s)||8|
|Published online||12 September 2022|
CBP/p300 bromodomain: new promising epigenetic target
HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo 315000, China
2 Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo 315000, China
3 International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China
4 Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, 510530, China
5 China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou, 510530, China
6 State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China
* Corresponding author: email@example.com
Accepted: 17 August 2022
CREB (cAMP responsive element binding protein) binding protein (CBP) and adenovirus E1A-associated 300 kDa protein (p300) are histone acetyltransferases, which are necessary for multiple cellular processes. Thus, CBP/p300 are promising potential antitumor targets. To date, despite various small molecule inhibitors of CBP/p300 bromodomain (BRD) having been reported, no specific inhibitor was approved by U.S. Food and Drug Administration (FDA). In this review, we described the discovery, optimization, binding mode evaluation, selectivity and potency evaluation, and therapeutic opportunities of our CBP/p300 bromodomain inhibitors, aiming to inspire new inhibitor design and advance drug discovery research in this field. One video presents the development of CBP/p300 bromodomain inhibitors.
Key words: CBP/p300 / Bromodomain / Inhibitor / Prostate cancer
© The Authors, published by EDP Sciences, 2022
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.